Dentsply Sirona Q3 revenue misses estimates as dental segment sales decline

By Reuters News


Overview

  • Dental products maker's Q3 revenue fell 7.6% yr/yr, missing analyst expectations

  • Adjusted EPS for Q3 dropped 29% yr/yr

  • Results included a $39 mln one-time inventory accounting benefit, while Wellspect Healthcare posted record quarterly sales


Outlook

  • Dentsply Sirona updates 2026 net sales outlook to about $3.5 bln

  • Company expects 2026 adjusted EPS of $1.20-$1.30, excluding a $0.17 one-time tariff refund benefit


Result Drivers

  • WELLSPECT HEALTHCARE - Co achieved record quarterly sales for Wellspect Healthcare, with 10.1% as-reported growth

  • INDUSTRY CONDITIONS - Co said challenging industry-wide conditions weighed on results, per CEO Dan Scavilla

  • BROAD-BASED SALES DECLINE - Constant-currency sales fell 7%, with declines across Connected Technology, Essential Dental and Orthodontic and Implant Solutions


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$836 mln

$862 mln (14 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 13 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

  • Wall Street's median 12-month price target for DENTSPLY SIRONA Inc. is $12.00, about 12.7% above its November 4 closing price of $10.65

  • The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 9 three months ago


Reuters Recommended Reads

  • Nov 4 - Envista Q3 sales rise 3.2%, slightly beat estimates

  • Nov 4 - Netherlands' Qiagen Q3 sales, adjusted EPS top outlook; suspends 2026 guidance

  • Nov 4 - Zimmer Biomet Q3 sales beat estimates, raises FY outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk